BG
ACHN

BlackRock Group’s Achillion Pharmaceuticals ACHN Stock Holding History

BlackRock Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$589K Buy
142,479
+49,821
+54% +$265K ﹤0.01% 2305
2016
Q3 		$750K Buy
92,658
+44,678
+93% +$380K ﹤0.01% 2162
2016
Q2 		$374K Buy
47,980
+1,045
+2% +$8.96K ﹤0.01% 2363
2016
Q1 		$363K Buy
46,935
+14,220
+43% +$104K ﹤0.01% 2361
2015
Q4 		$352K Sell
32,715
-747
-2% -$6.79K ﹤0.01% 2333
2015
Q3 		$231K Buy
33,462
+4,550
+16% +$37.1K ﹤0.01% 2489
2015
Q2 		$256K Buy
28,912
+8,679
+43% +$82.1K ﹤0.01% 2514
2015
Q1 		$200K Buy
20,233
+10,308
+104% +$129K ﹤0.01% 2496
2014
Q4 		$121K Sell
9,925
-3,636
-27% -$44.4K ﹤0.01% 2637
2014
Q3 		$136K Buy
13,561
+12,300
+975% +$114K ﹤0.01% 2540
2014
Q2 		$10K Hold
1,261
– – ﹤0.01% 2794
2014
Q1 		$4K Hold
1,261
– – ﹤0.01% 2735
2013
Q4 		$4K Hold
1,261
– – ﹤0.01% 2651
2013
Q3 		$4K Hold
1,261
– – ﹤0.01% 2879
2013
Q2 		$10K Buy
+1,261
New +$9.63K ﹤0.01% 2559

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock Group's ACHN Position: Q4 2016 in Review

BlackRock Group increased its Achillion Pharmaceuticals (ACHN) stake by 54% in Q4 2016, buying an estimated $265K and bringing the position to 142,479 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

BlackRock Group first reported a position in ACHN in Q2 2013 and has held it in 15 quarters since. The position peaked at $750K in Q3 2016. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • BlackRock Group held 142,479 shares of Achillion Pharmaceuticals worth $589K as of Q4 2016.
  • BlackRock Group bought 49,821 Achillion Pharmaceuticals shares in Q4 2016, an estimated $265K.
  • Achillion Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2305 holding.
  • BlackRock Group first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Achillion Pharmaceuticals position peaked at $750K in Q3 2016.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.